(CRSP) Crispr Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: Switzerland • Currency: USD • Type: Common Stock • ISIN: CH0334081137

CRSP: Gene, Editing, Therapies, Cancer, Diabetes, Stem, Cells

CRISPR Therapeutics AG, a pioneer in gene editing, is at the forefront of developing innovative gene-based therapies for severe human diseases. Their proprietary CRISPR/Cas9 platform enables precise modifications to genomic DNA, offering a transformative approach to treating genetic disorders. The companys diverse pipeline spans hemoglobinopathies, immune-oncology, autoimmune diseases, and type 1 diabetes, showcasing its broad therapeutic reach.

Their lead candidate, CASGEVY, exemplifies this innovation—an ex vivo CRISPR/Cas9 gene-edited cell therapy designed for transfusion-dependent beta-thalassemia and severe sickle cell disease. By editing hematopoietic stem cells to boost fetal hemoglobin production, CASGEVY addresses the root cause of these debilitating conditions, offering hope for patients seeking durable relief.

Complementing their ex vivo therapies, CRISPR Therapeutics is advancing an impressive in vivo pipeline. Programs like CTX310 and CTX320 target cardiovascular diseases by disrupting specific proteins, demonstrating their strategic approach to tackling complex conditions. Additionally, their allogeneic stem cell-derived product, VCTX211, aims to revolutionize type 1 diabetes treatment, highlighting their commitment to cutting-edge solutions.

The companys strategic collaborations with industry leaders such as Vertex Pharmaceuticals underscore its collaborative ethos, enhancing their ability to bring groundbreaking therapies to market. With a robust portfolio and a strong financial position, CRISPR Therapeutics AG is well-positioned to lead in the biotechnology sector, supported by a market cap exceeding $3.3 billion and forward P/E of 23.36, reflecting investor confidence in their growth potential.

Additional Sources for CRSP Stock

CRSP Stock Overview

Market Cap in USD 2,801m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2016-10-19

CRSP Stock Ratings

Growth Rating -51.3
Fundamental -
Dividend Rating 0.0
Rel. Strength -24.1
Analysts 3.79/5
Fair Price Momentum 31.39 USD
Fair Price DCF -

CRSP Dividends

No Dividends Paid

CRSP Growth Ratios

Growth Correlation 3m -61%
Growth Correlation 12m -84.2%
Growth Correlation 5y -74.6%
CAGR 5y -6.19%
CAGR/Max DD 5y -0.07
Sharpe Ratio 12m -1.03
Alpha -38.57
Beta 1.829
Volatility 78.57%
Current Volume 1832.1k
Average Volume 20d 2195.4k
What is the price of CRSP stocks?
As of April 23, 2025, the stock is trading at USD 39.23 with a total of 1,832,126 shares traded.
Over the past week, the price has changed by +0.72%, over one month by -7.95%, over three months by -11.24% and over the past year by -29.52%.
Is Crispr Therapeutics a good stock to buy?
No, based on ValueRay Analyses, Crispr Therapeutics (NASDAQ:CRSP) is currently (April 2025) a stock to sell. It has a ValueRay Growth Rating of -51.33 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CRSP as of April 2025 is 31.39. This means that CRSP is currently overvalued and has a potential downside of -19.98%.
Is CRSP a buy, sell or hold?
Crispr Therapeutics has received a consensus analysts rating of 3.79. Therefor, it is recommend to hold CRSP.
  • Strong Buy: 11
  • Buy: 4
  • Hold: 11
  • Sell: 0
  • Strong Sell: 2
What are the forecast for CRSP stock price target?
According to ValueRays Forecast Model, CRSP Crispr Therapeutics will be worth about 35.8 in April 2026. The stock is currently trading at 39.23. This means that the stock has a potential downside of -8.64%.
Issuer Forecast Upside
Wallstreet Target Price 84.6 115.7%
Analysts Target Price 84.1 114.3%
ValueRay Target Price 35.8 -8.6%